The pharmaceutical industry has asked the Drug Controller General of India (DCGI) for more time to phase out fixed-dose combinations (FDCs), a mix of approved drugs, from the Indian market.

The industry has also urged the DCGI to adopt a practical approach and come up with clear-cut guidelines on this issue. “We have asked the DCGI to legalise the safe FDCs available in the market and to develop specific rules for licensing such drugs. The DCGI’s office in the past had legalised many such drugs. If there are proven harmful combinations, we will support their withdrawal and the industry should be given adequate time for withdrawing such combinations,” said Daara Patel, secretary general of Indian Drugs Manufacturers Association (IDMA).

Read More...